| Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade SJ Dovedi, AL Adlard, G Lipowska-Bhalla, C McKenna, S Jones, ... Cancer research 74 (19), 5458-5468, 2014 | 1235 | 2014 |
| Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study B Pro, R Advani, P Brice, NL Bartlett, JD Rosenblatt, T Illidge, J Matous, ... Journal of clinical oncology 30 (18), 2190-2196, 2012 | 1126 | 2012 |
| Consensus guidelines for the detection of immunogenic cell death O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ... Oncoimmunology 3 (9), e955691, 2014 | 837 | 2014 |
| Consensus guidelines for the definition, detection and interpretation of immunogenic cell death L Galluzzi, I Vitale, S Warren, S Adjemian, P Agostinis, AB Martinez, ... Journal for immunotherapy of cancer 8 (1), 2020 | 804 | 2020 |
| Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma J Radford, T Illidge, N Counsell, B Hancock, R Pettengell, P Johnson, ... New England Journal of Medicine 372 (17), 1598-1607, 2015 | 792 | 2015 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 691 | 2019 |
| Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial CA Meyers, JA Smith, A Bezjak, MP Mehta, J Liebmann, T Illidge, ... Journal of clinical oncology 22 (1), 157-165, 2004 | 677 | 2004 |
| The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant K Reynders, T Illidge, S Siva, JY Chang, D De Ruysscher Cancer treatment reviews 41 (6), 503-510, 2015 | 610 | 2015 |
| Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG) L Specht, J Yahalom, T Illidge, AK Berthelsen, LS Constine, HT Eich, ... International Journal of Radiation Oncology* Biology* Physics 89 (4), 854-862, 2014 | 599 | 2014 |
| Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up DA Eichenauer, BMP Aleman, M André, M Federico, M Hutchings, ... Annals of Oncology 29, iv19-iv29, 2018 | 589* | 2018 |
| Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial L Lowry, P Smith, W Qian, S Falk, K Benstead, T Illidge, D Linch, ... Radiotherapy and Oncology 100 (1), 86-92, 2011 | 407 | 2011 |
| Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group J Yahalom, T Illidge, L Specht, RT Hoppe, YX Li, R Tsang, A Wirth, ... International Journal of Radiation Oncology* Biology* Physics 92 (1), 11-31, 2015 | 364 | 2015 |
| Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies W Alduaij, A Ivanov, J Honeychurch, EJ Cheadle, S Potluri, SH Lim, ... Blood, The Journal of the American Society of Hematology 117 (17), 4519-4529, 2011 | 353 | 2011 |
| Modern radiation therapy for nodal non-Hodgkin lymphoma—target definition and dose guidelines from the International Lymphoma Radiation Oncology Group T Illidge, L Specht, J Yahalom, B Aleman, AK Berthelsen, L Constine, ... International Journal of Radiation Oncology* Biology* Physics 89 (1), 49-58, 2014 | 299 | 2014 |
| Clinical development of new drug–radiotherapy combinations RA Sharma, R Plummer, JK Stock, TA Greenhalgh, O Ataman, S Kelly, ... Nature reviews Clinical oncology 13 (10), 627-642, 2016 | 285 | 2016 |
| Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up DA Eichenauer, A Engert, M André, M Federico, T Illidge, M Hutchings, ... Annals of oncology 25, iii70-iii75, 2014 | 273 | 2014 |
| Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma B Pro, R Advani, P Brice, NL Bartlett, JD Rosenblatt, T Illidge, J Matous, ... Blood, The Journal of the American Society of Hematology 130 (25), 2709-2717, 2017 | 245 | 2017 |
| guideline Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. D Oscier, C Fegan, P Hillmen, T Illidge, S Johnson, P Maguire, E Matutes, ... British journal of haematology 125 (3), 2004 | 237 | 2004 |
| Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells A Ivanov, SA Beers, CA Walshe, J Honeychurch, W Alduaij, KL Cox, ... The Journal of clinical investigation 119 (8), 2143-2159, 2009 | 233 | 2009 |
| Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell … F Morschhauser, T Illidge, D Huglo, G Martinelli, G Paganelli, PL Zinzani, ... Blood, The Journal of the American Society of Hematology 110 (1), 54-58, 2007 | 208 | 2007 |
